UNITED STATES
                       SECURITIES AND EXCHANGE COMMISSION
                             Washington, D.C. 20549

                                    FORM 10-Q
(Mark One)

[X]  QUARTERLY  REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES  EXCHANGE ACT
     OF 1934

                For the quarterly period ended November 30, 2008

[_]  TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE EXCHANGE ACT

                 For the transition period from _____ to _______

                       Commission File Number: 333-107179

                          CANCER DETECTION CORPORATION
             (Exact Name of Registrant as Specified in its Charter)

                  Nevada                                      98-0380519
     (State or other jurisdiction of                       (I.R.S. Employer
      incorporation or organization)                       Identification No.)

                 10965 Elizabeth Drive, Conifer, Colorado 80433
               (Address of Principal Executive Offices) (Zip Code)

        Registrant's telephone number including area code: (303) 908-4900

                                       N/A
--------------------------------------------------------------------------------
              Former name, former address, and former fiscal year,
                          if changed since last report

Indicate by check mark whether the registrant (1) filed all reports  required to
be filed by Section 13 or 15(d) of the  Securities  Exchange  Act of 1934 during
the past 12 months (or for such shorter  period that the registrant was required
to file such reports),  and (2) has been subject to such filing requirements for
the past 90 days. Yes [X]        No [_]

Indicate by check mark whether the registrant is a large  accelerated  filer, an
accelerated filer, a non-accelerated  filer, or a smaller reporting company. See
definition  of "large  accelerated  filer,"  "accelerated  filer"  and  "smaller
reporting company" in Rule 12b-2 of the Exchange Act.

Larger accelerated filer [_]                               Accelerated filer [_]
Non-accelerated filer [_}                          Smaller reporting company [X]

Indicate by check mark whether registrant is a shell company (as defined in Rule
12b-2 of the Exchange Act).     Yes [_]    No [X]

Indicate the number of shares  outstanding  of each of the  issuer's  classes of
common stock, as of the latest  practicable  date:  16,353,124  shares of common
stock, par value $0.001, outstanding as of January 13, 2009.


================================================================================


<PAGE>


<TABLE>
<CAPTION>

                                  CANCER DETECTION CORPORATION

                                              Index

                                                                                                            Page
<S>              <C>                                                                                        <C>

Item 1.          Financial Statements

                 Consolidated Balance Sheets at November 30, 2008 (unaudited) and May 31, 2008                1

                 Consolidated Statements of Operations for the three months and six months ended              2
                 November 30, 2008 and 2007 and for the period from inception to
                 November 30, 2008 (unaudited)

                 Consolidated Statements of Cash Flow for the six months ended November 30, 2008 and          3
                 2007 and for the period from inception to November 30, 2008 (unaudited)

                 Notes to Consolidated Financial Statements (unaudited)                                       4

Item 2.          Management's Discussion and Analysis of Financial Condition and Results of Operation         9

Item 3.          Quantative and Qualitative Disclosure about Market Risk                                     N/A

Item 4.          Controls and Procedures                                                                     N/A

Item 4T.         Controls and Procedures                                                                     13

Part II - OTHER INFORMATION

Item 1.           Legal Proceedings                                                                          14

Item 2.           Unregistered Sales of Equity Securities and Use of Proceeds                                14

Item 3.           Defaults upon Senior Securities                                                            14

Item 4.           Submission of Matters to a Vote of Security Holders                                        14

Item 5.           Other Information                                                                          14

Item 6.           Exhibits                                                                                   15

SIGNATURES                                                                                                   16
</TABLE>



<PAGE>


                         PART I - FINANCIAL INFORMATION

ITEM 1.  Financial Statements


<TABLE>
<CAPTION>

                 CANCER DETECTION CORPORATION AND SUBSIDIARY
                      (formerly Xpention Genetics, Inc.)
                        (A Development Stage Company)
                         CONSOLIDATED BALANCE SHEETS


                                                                                November 30,           May 31,
                                                                                    2008                2008
                                                                               ----------------    ----------------
                                                                                 (Unaudited)

                                          ASSETS
<S>                                                                            <C>                 <C>

Current assets
     Cash and cash equivalents                                                         $ 9,410                $ 50
     Prepaid expenses                                                                    6,663                   -
                                                                               ----------------    ----------------
            Total assets                                                              $ 16,073                $ 50
                                                                               ================    ================


                         LIABILITIES AND STOCKHOLDERS' (DEFICIT)

Current liabilities
     Accounts payable and accrued expenses                                           $ 138,050           $ 149,664
     Accrued compensation                                                              392,000             344,000
     Accrued interest                                                                    2,280              17,344
     Advances from related parties                                                           -              15,000
     Notes payable, related party                                                            -             113,600
     Convertible debt                                                                   15,000              30,000
                                                                               ----------------    ----------------
            Total current liabilities                                                  547,330             669,608
                                                                               ----------------    ----------------

Stockholders' (deficit)
     Preferred stock, $0.001 par value, 10,000,000 shares authorized,
        none issued or outstanding                                                           -                   -
     Common stock, $0.001 par value, 100,000,000 shares authorized,
        12,353,124 and 2,998,826 shares issued and outstanding
        at November 30, 2008 and May 31, 2008, respectively                             12,353               2,999
     Additional paid-in capital                                                      1,252,298             978,101
     (Deficit) accumulated during the development stage                             (1,795,908)         (1,650,658)
                                                                               ----------------    ----------------
            Total stockholders' (deficit)                                             (531,257)           (669,558)
                                                                               ----------------    ----------------
            Total liabilities and stockholders' (deficit)                             $ 16,073                $ 50
                                                                               ================    ================
</TABLE>


   The accompanying notes are an integral part of these financial statements.

                                       1

<PAGE>

<TABLE>
<CAPTION>

                           CANCER DETECTION CORPORATION AND SUBSIDIARY
                               (formerly Xpention Genetics, Inc.)
                                  (A Development Stage Company)
                              CONSOLIDATED STATEMENTS OF OPERATIONS
              for the three months and six months ended November 30, 2008 and 2007,
           and for the period from Inception (October 13, 2004) to November 30, 2008
                                           (Unaudited)



                                                                                                                 October 13, 2004
                                         Three Months Ended November 30,       Six Months Ended November 30,      (Inception) to
                                         2008               2007              2008               2007           November 30, 2008
                                     --------------     --------------    --------------     --------------     -------------------
<S>                                  <C>                <C>               <C>                <C>                <C>

Revenues                                  $      -            $     -           $     -            $     -   -           $       -
                                     --------------     --------------    --------------     --------------     -------------------

Expenses
   Research and development                 49,239                  -            50,819             28,065                 988,420
   General and administrative               52,982             40,361            93,035             79,235                 649,148
                                     --------------     --------------    --------------     --------------     -------------------
        Total expenses                     102,221             40,361           143,854            107,300               1,637,568
                                     --------------     --------------    --------------     --------------     -------------------

Operating (loss)                          (102,221)           (40,361)         (143,854)          (107,300)             (1,637,568)
                                     --------------     --------------    --------------     --------------     -------------------

Other (expense)
   Interest expense                           (356)            (1,979)           (1,396)            (3,929)                (23,740)
   Amortization of debt discount                 -           (118,836)                -           (124,129)               (134,600)
                                     --------------     --------------    --------------     --------------     -------------------
        Total other (expense)                 (356)          (120,815)           (1,396)          (128,058)               (158,340)
                                     --------------     --------------    --------------     --------------     -------------------

Net (loss)                              $ (102,577)        $ (161,176)       $ (145,250)        $ (235,358)           $ (1,795,908)
                                     ==============     ==============    ==============     ==============     ===================


Net (loss) per common share:
   Basic and diluted                    $ (0.01)           $    (0.05)       $    (0.02)           $ (0.08)
                                     ==============     ==============    ==============     ==============

Weighted average shares outstanding:
   Basic and diluted                     8,806,421          2,998,792         6,506,518          2,998,792
                                     ==============     ==============    ==============     ==============
</TABLE>


   The accompanying notes are an integral part of these financial statements.

                                       2

<PAGE>

<TABLE>
<CAPTION>

                   CANCER DETECTION CORPORATION AND SUBSIDIARY
                       (formerly Xpention Genetics, Inc.)
                          (A Development Stage Company)
                      CONSOLIDATED STATEMENTS OF CASH FLOWS
              for the six months ended November 30, 2008 and 2007,
    and for the period from Inception (October 13, 2004) to November 30, 2008
                                   (Unaudited)


                                                                                        October 13, 2004
                                                                                         (Inception) to
                                                        2008               2007         November 30, 2008
                                                    --------------    ---------------   ------------------
<S>                                                 <C>               <C>               <C>

Cash flows from operating activities:
      Net (loss)                                       $ (145,250)        $ (235,358)        $ (1,795,908)
                                                    --------------    ---------------   ------------------
      Adjustments to reconcile net (loss) to
          net cash used in operating activities:
          Stock based compensation                          5,500                  -              376,900
          Amortization of debt discount                         -            124,129              134,600
      Changes in operating assets and liabilities:
          Prepaid expenses                                 (6,663)            (9,562)              (6,663)
          Accounts payable and accrued expenses            35,773             85,668              546,781
                                                    --------------    ---------------   ------------------
      Total adjustments                                    34,610            200,235            1,051,618
                                                    --------------    ---------------   ------------------

          Cash flows (used in) operating activities      (110,640)           (35,123)            (744,290)
                                                    --------------    ---------------   ------------------

Cash flows from investing activities:
                                                    --------------    ---------------   ------------------
          Cash flows (used in) investing activities             -                  -                    -
                                                    --------------    ---------------   ------------------

Cash flows from financing activities:
      Proceeds from note payable                                -              5,600              113,600
      Proceeds from convertible debt                            -                  -               30,000
      Principal payments on convertible debt              (15,000)                 -              (15,000)
      Advances from related parties                        28,750              5,000               53,750
      Repayment of advances from related parties          (43,750)                 -              (53,750)
      Proceeds from issuance of common stock              150,000                  -              625,100
                                                    --------------    ---------------   ------------------
          Cash flows provided by financing activities     120,000             10,600              753,700
                                                    --------------    ---------------   ------------------

Net increase (decrease) in cash and equivalents             9,360            (24,523)               9,410

Cash and cash equivalents, beginning of period                 50             24,707                    -
                                                    --------------    ---------------   ------------------

Cash and cash equivalents, end of period                  $ 9,410              $ 184              $ 9,410
                                                    ==============    ===============   ==================


Supplemental cash flow information:

        Income taxes paid                                     $ -                $ -                  $ -
                                                    ==============    ===============   ==================

        Interest paid                                     $ 2,009                $ -              $ 7,009
                                                    ==============    ===============   ==================


Non-cash investing and financing activities:

      Conversion of convertible debt and accrued
          interest to common shares                     $ 128,051                $ -            $ 128,051
                                                    ==============    ===============   ==================
</TABLE>

   The accompanying notes are an integral part of these financial statements.


                                       3

<PAGE>


                   CANCER DETECTION CORPORATION AND SUBSIDIARY
                       (Formerly Xpention Genetics, Inc.)
                          (A Development Stage Company)
                   NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
                                November 30, 2008
                                   (Unaudited)

NOTE  1.  ORGANIZATION,  BASIS  OF  PRESENTATION,  AND  SUMMARY  OF  SIGNIFICANT
ACCOUNTING POLICIES

Interim Financial Information

         The interim consolidated financial statements included herein have been
prepared  by the  Company,  without  audit,  in  accordance  with the  rules and
regulations of the Securities and Exchange  Commission  ("SEC") pursuant to Item
210 of Regulation S-X.  Certain  information and footnote  disclosures  normally
included  in  financial   statements  prepared  in  accordance  with  accounting
principles  generally  accepted in the United States of America ("US GAAP") have
been condensed or omitted pursuant to such SEC rules and  regulations,  although
the Company  believes  that the  disclosures  included  are adequate to make the
information presented not misleading.

         In management's  opinion, the consolidated balance sheet as of November
30, 2008 (unaudited),  the unaudited  consolidated  statements of operations for
the three month and six month periods ended  November 30, 2008 and 2007, and the
unaudited consolidated  statements of cash flows for the six month periods ended
November  30,  2008  and  2007,  contained  herein,   reflect  all  adjustments,
consisting  solely of normal recurring  items,  which are necessary for the fair
presentation of our financial position, results of operations, and cash flows on
a  basis  consistent  with  that of our  prior  audited  consolidated  financial
statements.  However,  the results of operations for interim  periods may not be
indicative of results to be expected for the full fiscal year. Therefore,  these
financial  statements  should be read in conjunction with the audited  financial
statements  and notes  thereto and summary of  significant  accounting  policies
included in the Company's Form 10-KSB for the year ended May 31, 2008.

Reverse Stock Split and Name Change

         On September 10, 2008, the Board of Directors of the Company approved a
reverse  stock  split of the common  stock in the ratio of 1 for 20 and the name
change  from  Xpention  Genetics,  Inc.  to Cancer  Detection  Corporation.  The
resolutions became effective September 17, 2008, when the State of Nevada issued
a  Certificate  of  Amendment  to  the  Company's   Articles  of  Incorporation.
Stockholders holding a majority of outstanding shares approved the reverse split
and the name change  amendment on July 25, 2008, by written consent in lieu of a
meeting of stockholders.  As a result of the Company's name change,  its trading
symbol on the Over-the-Counter Bulletin Board was changed to "CCDC."

Organization

         Cancer  Detection   Corporation  (the  "Company")   (formerly  Xpention
Genetics,  Inc.)  is a  Nevada  corporation  that  resulted  from  the  business
combination  between  Xpention,  Inc. and Bayview  Corporation  that occurred in
March, 2005. For accounting  purposes,  the date of inception for the Company is
October 13, 2004, the date that Xpention, Inc. was incorporated. The Company has
been in the  development  stage since its formation and has not yet realized any
revenues  from  its  planned  operations.  It is  engaged  in the  biotechnology

                                       4

<PAGE>

industry to develop both  immunological and molecular tests for cancer detection
in  animals  and  humans as well as  therapeutic  vaccines  and other  treatment
methods for both canine and human cancers. The Company's fiscal year ends on May
31.

Basis of Presentation

         Cancer Detection Corporation  represents the result of a merger between
Bayview Corporation ("Bayview"), a public company, and Xpention, Inc., a private
company. During March 2005, Bayview issued 715,000 shares of its common stock to
the sole  shareholder  of  Xpention,  Inc. in exchange for all of the issued and
outstanding common shares of Xpention, Inc. pursuant to an Agreement and Plan of
Reorganization  (the  "Merger").  In addition,  concurrent  with the exchange of
shares,  Bayview  changed its name to Xpention  Genetics,  Inc.,  whose name has
subsequently been changed to Cancer Detection Corporation as described above.

         For accounting purposes, this acquisition of Xpention, Inc. by Bayview,
a non-operating  entity,  represents a reverse acquisition under which Xpention,
Inc. is  recognized as the  accounting  acquirer.  In substance,  the Merger was
recorded as a capital  transaction by the issuance of 2,127,159 shares of common
stock by the  Company  for all of the issued and  outstanding  common  shares of
Bayview. No goodwill or other intangible assets were recorded and the historical
financial  statements  as of and prior to the  acquisition  date  represent  the
operations of Xpention, Inc.

         Xpention, Inc. (a wholly-owned  subsidiary of the Company) was incorpo-
rated in the State of  Colorado  on  October  13,  2004.  Since  its  inception,
Xpention,  Inc. has participated in the  biotechnology  industry to develop both
immunological  and molecular tests for cancer detection in animals and humans as
well as  therapeutic  vaccines and other  treatment  methods for both canine and
human cancers.

         Bayview was incorporated in the State of Nevada,  on September 5, 2002.
From  inception  until February 28, 2005,  Bayview was primarily  engaged in the
acquisition and exploration of mining  properties,  but had ceased operations by
February  28, 2005.  As of the date of the Merger,  Bayview had no assets and no
operations and has been treated as the acquired company for accounting purposes.

Development Stage Company

         The Company  presents its financial  statements in conformity  with the
accounting  principles  generally  accepted in the United States of America that
apply to enterprises that are establishing  their  operations.  As a development
stage enterprise, the Company must utilize accounting principles consistent with
those required of an established enterprise, and, in addition, must disclose the
deficit  accumulated during the development stage and the cumulative  statements
of  operations  and cash flows from  commencement  of  development  stage to the
current balance sheet date.

Basis of Consolidation

         The  consolidated  financial  statements  include  the  accounts of the
Company  and  its  wholly-owned  subsidiary,   Xpention,  Inc.  All  significant
intercompany accounts and transactions have been eliminated in consolidation.

Use of Estimates

         The  preparation  of financial  statements in  conformity  with US GAAP
requires  management to make estimates and assumptions  that affect the reported
amount of assets  and  liabilities  and  disclosure  of  contingent  assets  and
liabilities at the date of the financial  statements and the reported amounts of
revenues and expenses during the reporting  period.  Management  routinely makes

                                       5

<PAGE>

judgments  and  estimates  about the  effects  of  matters  that are  inherently
uncertain. Management bases its estimates and judgments on historical experience
and on various  other  factors  that are  believed  to be  reasonable  under the
circumstances,  the results of which form the basis for making  judgments  about
the carrying values of assets and liabilities that are not readily apparent from
other sources.  Future results could differ from these estimates.  Estimates and
assumptions are revised  periodically and the effects of revisions are reflected
in the financial statements in the period it is determined to be necessary.

Per Share Amounts

         SFAS 128, "Earnings Per Share," provides for the calculation of "Basic"
and "Diluted"  earnings per share. Basic earnings per share includes no dilution
and is computed by dividing net income (or loss) by the weighted-average  number
of shares outstanding during the period. Diluted earnings per share reflects the
potential  dilution  of  securities  that  could  share in the  earnings  of the
Company, assuming the issuance of an equivalent number of common shares pursuant
to options,  warrants,  or convertible debt  arrangements.  Diluted earnings per
share is not shown for  periods in which the  Company  incurs a loss  because it
would be  anti-dilutive.  Similarly,  potential common stock equivalents are not
included in the calculation if the effect would be anti-dilutive.

         All per share  amounts  presented  herein have been restated to reflect
the effect of the 1 for 20 reverse stock split approved on September 10, 2008.

Recent Accounting Pronouncements

         There were no accounting standards and interpretations  issued recently
which  are  expected  to a have a  material  impact on the  Company's  financial
position, operations or cash flows.

NOTE 2.  GOING CONCERN

         The accompanying  consolidated  financial statements have been prepared
in conformity with US GAAP, which contemplates  continuation of the Company as a
going concern.

         The  Company  is in its  development  stage  and has not yet  generated
revenues from operations.  It has experienced losses from operations as a result
of its investment  necessary to achieve its operating plan,  which is long-range
in nature.  For the six months ended November 30, 2008,  the Company  incurred a
net loss of $145,250,  and has incurred a cumulative net loss since inception of
$1,795,908.  At November 30, 2008, the Company had a working capital deficit and
stockholders'  deficit of  $531,257  and has no revenue  generating  operations.
These  conditions  raise  substantial  doubt about the ability of the Company to
continue as a going concern.

         Management  does  not  believe  that  the  Company's   current  capital
resources  will be sufficient  to fund its operating  activity and other capital
resource  demands  during fiscal year 2009 and is currently  seeking  additional
resources.  The  Company's  ability to continue as a going concern is contingent
upon its  ability to obtain  capital  through  the sale of equity or issuance of
debt, joint venture or sale of its assets, and ultimately  attaining  profitable
operations.  Recent  events  in  worldwide  capital  markets  may  make  it more
difficult for us to raise additional equity or capital.

         The financial  statements do not include any adjustments to reflect the
possible future effects on the  recoverability  and  classification of assets or
the amounts and  classification of liabilities that may result from the possible
inability of the Company to continue as a going concern.

                                       6

<PAGE>

NOTE 3.  NOTES PAYABLE, RELATED PARTY

         Effective  June 30, 2008,  The Regency  Group,  LLC  ("Regency  Group")
converted the outstanding  principal of $113,600 and accrued interest of $14,451
into 1,829,298 (post-split) shares of common stock.

NOTE 4.  CONVERTIBLE DEBT

         Effective January 5, 2007, the Company issued convertible debentures in
the aggregate  principal  amount of $30,000 to two debt holders.  The debentures
bear interest at 8% per annum and were  originally  due on January 5, 2008.  The
due date was subsequently  extended,  as discussed below. The debenture  holders
may convert the principal and accrued  interest into the Company's  common stock
at a rate of $0.20 per share.  Regency  Group holds  $15,000 of the  convertible
debt.

         Both debt  holders  agreed to  extend  the due date of the  convertible
debentures to April 30, 2008. During the six months ended November 30, 2008, the
Company  repaid one debt holder the  principal  balance of $15,000  plus accrued
interest of $2,009.  Regency  Group agreed to extend the due date of the $15,000
principal  balance  held  by them to  December  31,  2008,  and the  Company  is
currently negotiating an additional extension.

NOTE 5.  STOCKHOLDERS' (DEFICIT)

         On September 10, 2008, the board of directors  approved a resolution to
affect a 1 for 20 reverse  stock split,  which became  effective  September  17,
2008,  when the  State  of  Nevada  issued a  Certificate  of  Amendment  to the
Company's  Articles of  Incorporation.  One share of common  stock was issued in
replacement  of each 20 shares  outstanding  as of the July 24, 2008, the record
date, and the number of authorized  shares did not change.  All of the financial
information in this report has been adjusted to reflect the effect of this 1 for
20 reverse stock split.  As a result of the Company's  name change,  its trading
symbol on the Over-the-Counter Bulletin Board was changed to "CCDC".

         Effective  June 30, 2008,  the Company  issued  1,829,298  (post-split)
shares of common stock for the conversion of $113,600 in  outstanding  principal
of notes payable and the related accrued interest of $14,451.

         Effective  September  10,  2008,  the Company  recorded the issuance of
25,000  (post-split)  shares of its common stock for investor relations services
performed in connection  with the reverse  stock split and the name change.  The
services  were valued at $5,500,  an amount  consistent  with the quoted  market
value of $0.22 per share on September 10, 2008.

         During the six months ended  November 30,  2008,  the Company  issued a
total  of  7,500,000  (post-split)  shares  of its  common  stock  in a  private
placement to two stockholders at $0.02 per share for cash proceeds of $150,000.

NOTE 6.  COMMITMENTS

         Effective  October 6, 2008,  the Company  entered into a revised  Assay
Development Proposal with Future Focus, an independent testing organization. The
proposal is composed of 4 major phases with an estimated  total cost of $82,000.
Phase 1, which  consists of testing with  commercially  available  antibodies to
p65, commenced during the quarter ended November 30, 2008.

         In September,  2008,  Xpention,  Inc. amended its Patent and Technology
License  Agreement  with the Board of Regents of The  University of Texas System
and The  University  of Texas M. D.  Anderson  Cancer  Center to extend the time
frame for  commercialization of a veterinary product an additional two years and
to extend the time frame for commercialization of  a human diagnostic product an

                                       7

<PAGE>

additional  three  years,  among  other  changes.  It  is  expected  that  these
extensions  will allow the Company to complete its research and begin  marketing
activities within the milestones established in the amended Agreement.

NOTE 7.  RELATED PARTY TRANSACTIONS

         During the six months ended  November 30,  2008,  the Company  received
cash advances of $28,750 from  stockholders.  The advances did not bear interest
and were due upon demand.  All of the advances were repaid prior to November 30,
2008.

NOTE 8.  SUBSEQUENT EVENT

         Subsequent to November 30, 2008, the Company  received cash proceeds of
$40,000  from the sale of  4,000,000  shares of  restricted  common stock to two
investors.












                                       8

<PAGE>


ITEM 2. Management's  Discussion and Analysis of Financial Condition and Results
of Operation

         The  following  discussion  should  be read  in  conjunction  with  our
unaudited financial statements and notes thereto,  which are included herein. In
connection  with,  and because we desire to take advantage of, the "safe harbor"
provisions of the Private  Securities  Litigation Reform Act of 1995, we caution
readers regarding certain forward looking statements in the following discussion
and  elsewhere  in this  report  and in any other  statement  made by, or on our
behalf,  whether  or not in future  filings  with the  Securities  and  Exchange
Commission.  Forward-looking  statements  are statements not based on historical
information and which relate to future operations, strategies, financial results
or other  developments.  Forward looking  statements are necessarily  based upon
estimates and assumptions that are inherently  subject to significant  business,
economic and  competitive  uncertainties  and  contingencies,  many of which are
beyond our control and many of which, with respect to future business decisions,
are subject to change.  These  uncertainties and contingencies can affect actual
results and could cause actual results to differ materially from those expressed
in any forward  looking  statements  made by, or on our behalf.  We disclaim any
obligation to update forward-looking statements.

         The  independent  registered  public  accounting  firm's  report on the
Company's financial  statements as of May 31, 2008, and for each of the years in
the  two-year  period  then  ended,   includes  a  "going  concern"  explanatory
paragraph,  that  describes  substantial  doubt about the  Company's  ability to
continue  as a going  concern.  Management's  plans  in  regard  to the  factors
prompting the  explanatory  paragraph are discussed  below and also in Note 2 to
the unaudited interim financial statements.

Plan of Operation

         The Company, through Xpention, Inc, its wholly-owned subsidiary,  holds
the exclusive  worldwide  license to a patented  technology for the detection of
cancer  based on a tumor marker  known as "p65" which has been  demonstrated  to
have  elevated  levels in the blood of canine and human cancer  conditions.  The
tumor marker "p65" is believed to be a protein required in the early development
of  numerous  cancers  and  appears  from  early  research  to  provide a strong
indication of tumor growth in both canines and humans. It also appears to have a
direct  correlation  to tumor  size/mass  making it a promising  marker for both
early  detection  of  malignant  tumor  formation  as well as a useful  tool for
monitoring  therapy and remission.  We plan to develop an immunological  test as
well as a molecular  assay for  detection of cancer in canines.  We also plan to
develop both immunological and molecular tests for detection of human cancers as
well as therapeutic treatments and vaccines.

         In September,  2008,  Xpention,  Inc. amended its Patent and Technology
License  Agreement  with the Board of Regents of The  University of Texas System
and The University of Texas M. D. Anderson  Cancer Center  ("UTMDACC") to extend
the time frame for  commercialization  of a veterinary product an additional two
years and to extend the time frame for  commercialization  of a human diagnostic
product an  additional  three years,  among other  changes.  It is expected that
these  extensions  will allow the Company to  complete  its  research  and begin
marketing activities within the milestones established in the amended Agreement.

         We contract  with third  party  research  organizations  to conduct our
research  activities.  During June 2007, we entered into an Assay Revalidation /
Redevelopment  Proposal with Future Focus, an independent testing  organization.
The project calls for third party validation of the research  results  presented
in the final report from the  University of Texas Health  Science  Center at San
Antonio  ("UTHSCSA")  and  technology  transfer of the current  assay plus assay
reformatting  and sample  analysis.  On August 15, 2007,  we announced  that the
researchers had been unable to replicate the results obtained at UTHSCSA.

                                       9

<PAGE>

         Effective  October 6, 2008,  the Company  entered into a revised  Assay
Development  Proposal with Future Focus,  composed of four major phases. Phase I
was completed in December,  2008, and Phase III, which is a commercial  contract
with AbD  Serotec,  a  German  biotechnology  company,  for the  preparation  of
recombinant  monoclonal  antibodies used in the research has been  substantially
completed as well.  Future Focus has now begun work on Phase IV,  consisting  of
assay formulation and canine serum sample analysis.

         As a result of the revalidation  results,  we are reviewing our planned
research  activities  for the  development  of an  immunological  canine  cancer
detection   test.   We  also   continue   to   evaluate   various   options  for
commercialization  of  products;  however,  it is not  anticipated  that we will
generate any revenues from  commercialization  of our technology during the next
twelve months.

         On September 10, 2008, the Board of Directors of the Company approved a
reverse  stock  split of the common  stock in the ratio of 1 for 20 and the name
change  from  Xpention  Genetics,  Inc.  to Cancer  Detection  Corporation.  The
resolutions became effective September 17, 2008, when the State of Nevada issued
a  Certificate  of  Amendment  to  the  Company's   Articles  of  Incorporation.
Stockholders holding a majority of outstanding shares approved the reverse split
and the name change  amendment on July 25, 2008, by written consent in lieu of a
meeting of stockholders.  As a result of the Company's name change,  its trading
symbol on the Over-the-Counter Bulletin Board was changed to "CCDC".

Liquidity and Capital Resources

         As of November 30, 2008,  our working  capital  deficit of $531,257 was
comprised of current assets of $16,073 and current liabilities of $547,330. This
represents an improvement in working capital of $138,301 compared to the deficit
of $669,558  at fiscal  year end May 31,  2008.  Our  working  capital  position
improved  primarily  because we received  cash  proceeds  of  $150,000  from the
private  placement  of  7,500,000  shares of common stock and because a creditor
converted certain indebtedness into common stock.

         Management  does  not  believe  that  the  Company's   current  capital
resources  will be sufficient  to fund its operating  activity and other capital
resource demands for the next twelve months.  Our ability to continue as a going
concern is  contingent  upon our ability to obtain  capital  through the sale of
equity or  issuance of debt,  joint  venture or sale of assets,  and  ultimately
attaining profitable  operations.  There is no assurance that we will be able to
successfully  complete any one of these  activities.  Recent events in worldwide
capital markets may make it more difficult for us to raise additional  equity or
capital.

         We are presently  seeking  additional  financing to provide  sufficient
funds for payment of amounts due under research contracts as well as accrued but
unpaid  professional  fees  and  administrative  expenses  and to  fund  ongoing
research and operations.

         We  have  never  received   revenue  from  our   operations.   We  have
historically  relied on equity and debt financings to fund our capital  resource
requirements.  We have experienced net losses since inception. We do not believe
that we are a candidate  for  conventional  debt  financing and we have not made
arrangements to borrow funds under a working capital line of credit.  We will be
dependent on  additional  financing  to continue  our  research and  development
efforts.

         All of our investment in research and  development  activities has been
expensed,  and does not appear as an asset on our balance sheet.  From inception
to November 30,  2008,  we have spent  $988,420 on our research and  development
efforts to commercialize the "p65" technology.

         All of our capital  resources  to date have been  provided  through the
sale  of  equity  securities,   proceeds  from  notes  payable  and  convertible
debentures,  and advances from related parties.  From inception through November
30, 2008, we received  $625,100 in cash through issuance of our common stock. In

                                       10

<PAGE>

addition,  we  received  cash  proceeds,  of  $143,600  from  various  borrowing
arrangements.  Since we have not  generated  any cash from  operations,  we have
relied on sale of equity and borrowings to fund all of our capital needs.

         Our ability to pay  accounts  payable and  accrued  expenses  and repay
borrowings is dependent upon receipt of new funding.  Certain  stockholders have
periodically advanced funds to us to meet our working capital needs. The related
parties are under no obligations to continue these advances.  As of November 30,
2008, all advances  received from related parties had been repaid and there were
no outstanding balances.

         Net cash used in  operating  activities  was  $110,640,  during the six
months ended November 30, 2008, compared to $35,123, during the six months ended
November 30, 2007, an increase of $75,517. Net cash used in operating activities
is closely  correlated  to cash  provided by financing  activities.  We used the
proceeds from our financing  activities to fund research and operating  expenses
and reduce accounts payable.

         During the six months ended November  30, 2008 and 2007,  the Company's
investment activities neither provided nor used any funds.

         Net cash provided by financing  activities  during the six months ended
November 30, 2008, was $120,000  compared to $10,600 during the six months ended
November 30, 2007.

         During the six months  ended  November 30,  2008,  we issued  7,500,000
shares of our common stock at $0.02 per share for cash proceeds of $150,000.  We
also  received  advances  from  related  parties  of  $28,750.  We used  cash in
financing  activities to repay advances to related parties of $43,750 and retire
convertible debt of $15,000.

         Our financing activities during the six months ended November 30, 2007,
provided  proceeds  from a note  payable of $5,600 and  advances  from a related
party of $5,000.

         In a non-cash  transaction  effective  June 30, 2008, The Regency Group
LLC (Regency Group) converted $113,600 of outstanding principal on notes payable
and $14,451 of related  accrued  interest  into  1,829,298  shares of our common
stock.  During the six months ended  November 30, 2008,  the due date of $15,000
convertible debt payable to Regency Group was extended to December 31, 2008, and
we are currently negotiating for an additional extension.

Results of  Operations - Three Months Ended  November 30, 2008 Compared to Three
Months Ended November 30, 2007

         We are considered a development stage company for accounting  purposes,
since we have not  received  any  revenues  from  operations.  We are  unable to
predict with any degree of accuracy when that situation  will change.  We expect
to incur losses until such time,  if ever, as we begin  generating  revenue from
operations.

         For the three months ended November 30, 2008, we recorded a net loss of
$102,577,  or $(0.01)  per share,  compared to a loss of $161,176 or $(0.05) per
share for the three months ended November 30, 2007.

         During the three  months ended  November 30, 2008 and 2007,  we did not
recognize any revenues from our operational activities.

         Research and development  costs were $49,239 for the three months ended
November  30,  2008,  compared to $nil  incurred  during the three  months ended
November 30,  2007.  Our use of third party  research  and testing  partners can
result in significant  variations in the expenses  reported in each period.  The
costs incurred during the three months ended November 30, 2008 represent amounts
paid to third  party  testing  organizations  and  $25,000  paid to  UTMDACC  in
connection with an amendment to our License Agreement.

                                       11

<PAGE>

         General and  administrative  expense increased to $52,982 for the three
months ended  November 30, 2008,  compared to $40,361  during the same period of
2007. The increase of $12,621 includes an increase of investor relations expense
of $6,244 and an  increase  of stock  compensation  costs of $5,500.  During the
three months ended November 30, 2008, we agreed to issue 25,000 shares of common
stock to an investor relations  consultant.  These increased costs were incurred
in connection with the Company's name change, reverse stock split, and increased
efforts to communicate  with  investors.  The primary  components of general and
administrative  expense are costs accrued for  compensation,  professional  fees
associated  with our status as a public  company,  and the premium  costs of D&O
insurance. D&O insurance decreased by $1,573, or 33%, as a result of obtaining a
less costly policy.

         Interest expense was $356 for the three months ended November 30, 2008,
compared to $120,815 for the three months ended November 30, 2007, a decrease of
$120,459 or 99%.  Included in interest  expense in 2007 is the  amortization  of
debt  discount in the amount of $118,836  related to the  beneficial  conversion
feature of the convertible  debentures  issued during 2007. The remainder of the
decrease in interest  expense is  attributable  to a  reduction  in  outstanding
principal balances of notes payable.

Results of  Operations - Six Months Ended  November 30, 2008 Compared to the Six
Months Ended November 30, 2007

         For the six months ended  November 30, 2008,  we recorded a net loss of
$145,250 or $(0.02) per share,  compared to a loss for the corresponding  period
of 2007 of $235,358 or $(0.08) per share, a difference of $90,108.

         During the six months  ended  November  30,  2008 and 2007,  we did not
recognize any revenues from our operational activities.

         Research and  development  costs  increased  to $50,819  during the six
months  ended  November 30, 2008,  compared to $28,065  incurred  during the six
months  ended  November 30, 2007.  The  increase of $22,754  primarily  reflects
$25,000  paid  to  UTMDACC  in  connection  with  an  amendment  to our  License
Agreement.  The  remaining  amounts  during  both  periods  were for third party
testing  costs  incurred to validate  the  results of the  research  report from
UTHSCSA.  Our use of third party  research  and testing  partners  can result in
significant variations in the expenses reported in each quarterly period.

         General and  administrative  expenses  increased to $93,085 for the six
months ended  November 30, 2008,  compared to $79,235  during the  corresponding
period of 2007.  The overall  increase of $13,800  includes  increased  investor
relations expense of $8,286 and stock compensation  costs of $5,500.  During the
six months ended  November 30, 2008,  we agreed to issue 25,000 shares of common
stock to an investor relations  consultant.  These increased costs were incurred
in connection with the Company's name change, reverse stock split, and increased
efforts to communicate  with  investors.  The primary  components of general and
administrative  expense are costs accrued for  compensation,  professional  fees
associated  with our status as a public  company,  and the premium  costs of D&O
insurance.

         Interest   expense,   including  the  amortization  of  debt  discount,
decreased  to $1,396 for the six months  ended  November  30,  2008  compared to
$128,058  for the  comparable  period in the prior year, a decrease of $126,662.
Interest  expense  reported during the 2007 period included the  amortization of
debt discount of $124,129  related to the beneficial  conversion  feature of the
convertible  indebtedness.  The costs  were not  repeated  during  2008.  As the
amortization costs are a non-cash item, they do not impact our liquidity.

         The remainder of the decrease in interest  expense is attributable to a
reduction in outstanding principal balances of notes payable.

                                       12

<PAGE>


ITEM 4T.  Controls and Procedures

         (a) During the fiscal period  covered by this report,  our  management,
with the  participation  of the Chief  Executive  Officer  and  Chief  Financial
Officer of the Company,  carried out an evaluation of the  effectiveness  of the
design and operation of our  disclosure  controls and  procedures (as defined in
Rules 13a-15(e) and 15d-15(e) of the Securities Exchange Act of 1934, as amended
(the "Exchange Act")). Based on such evaluation, our Chief Executive Officer and
Chief Financial  Officer has concluded that, as of the end of the period covered
by this report,  our disclosure  controls and procedures are effective to ensure
that  information  required  to be  disclosed  by us in reports  that we file or
submit under the Exchange Act is recorded,  processed,  summarized  and reported
within the required  time  periods and are  designed to ensure that  information
required to be disclosed in our reports is accumulated  and  communicated to our
management,  including our Chief Executive Officer and Chief Financial  Officer,
as appropriate to allow timely decisions regarding required disclosure.

         (b)  There  was  no  change  in our  internal  control  over  financial
reporting  that  occurred  during the quarter  ended  November 30, 2008 that has
materially affected,  or is reasonably likely to materially affect, our internal
control over financial reporting.















                                       13

<PAGE>


                           PART II - OTHER INFORMATION


Item 1.  LEGAL PROCEEDINGS

         No legal  proceedings  are  pending  or  threatened  to the best of our
knowledge.

Item 2.  UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS


         On October 31, 2008,  we issued 25,000 shares of our common stock to an
investor relations firm pursuant to an agreement dated July 25, 2008. The shares
were valued at $5,500, or $0.22 per share.

         On October  4,  2008,  we sold  3,750,000  shares of common  stock to a
private investor for cash proceeds of $75,000.

         On October 22,  2008,  we sold  3,750,000  shares of common  stock to a
private investment firm for cash proceeds of $75,000.

         On December 29,  2008,  we sold  2,000,000  shares of common stock to a
private investment firm for cash proceeds of $20,000.

         On January 12,  2009,  we sold  2,000,000  shares of common  stock to a
private investor for cash proceeds of $20,000.


Exemption From Registration Claimed

         All of the sales by the  Company of its  unregistered  securities  were
made by the Company in reliance upon Section 4(2) of the Securities Act of 1933,
as amended (the "1933 Act"). All of the individuals and/or entities listed above
that purchased the unregistered securities were all known to the Company and its
management,  through pre-existing  business  relationships.  All purchasers were
provided  access to all  material  information,  which they  requested,  and all
information  necessary to verify such  information  and were afforded  access to
management of the Company in connection with their purchases.  All purchasers of
the unregistered securities acquired such securities for investment and not with
a view  toward  distribution,  acknowledging  such  intent to the  Company.  All
certificates  or  agreements  representing  such  securities  that  were  issued
contained restrictive legends,  prohibiting further transfer of the certificates
or agreements representing such securities, without such securities either being
first registered or otherwise exempt from  registration in any further resale or
disposition.

Item 3.  DEFAULTS UPON SENIOR SECURITIES

         None

Item 4.  SUBMISSION OF MATTERS TO A VOTE OF SECURITY HOLDERS

         None.

Item 5.  OTHER INFORMATION

         None



                                       14

<PAGE>


Item 6.  EXHIBITS

         The following is a complete list of exhibits filed as part of this Form
10-Q. Exhibit numbers correspond to the numbers in the Exhibit Table of Item 601
of Regulation S-K.

         31    Certification of Chief Executive  Officer pursuant to Section 302
               of the Sarbanes-Oxley Act of 2002.

         32    Certification of Chief Executive  Officer pursuant to Section 906
               of the Sarbanes-Oxley Act of 2002.


<PAGE>



                                   SIGNATURES

         In accordance  with the  requirements  of Section 12 of the  Securities
Exchange Act of 1934, the Registrant has duly caused this Report to be signed on
its behalf by the undersigned, thereunto duly authorized.

                                         CANCER DETECTION CORPORATION


                                         By: /s/David Kittrell
Dated: January 15, 2009                      ----------------------------------
                                              David Kittrell,
                                              Chief Executive Officer, &
                                               Chief Financial Officer



















                                       16